Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.…
Kailera Therapeutics to Present at ObesityWeek 2026
Kailera Therapeutics (NASDAQ: KLRA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 145 employees.
The shares were at 11.02 USD on 20 November 2026. Its 52-week range is 9.760 USD to 28.23 USD: the price is 61.0% below the high and 12.9% above the low.
Its market capitalisation is 1.43B USD.
Kailera Therapeutics reports return on equity of 41.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 891.48M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 43.00 USD is 290.2% above the current price. The next earnings report is expected on 10 February 2027.